ArriVent BioPharma, Inc. Common Stock
$30.55
The Read: 3% rally on Q4 2025 earnings driven by positive pipeline optimism but then declined about 6% near Q1 2026 pre-PDUFA liquidity concerns, indicating moderate volatility and no large approval-driven spikes historically.
Price
Overlays
Panel
AVBP
Hover to view data
No Data